Upadacitinib outperforms dupilumab in restoring the fungal microbiome in atopic dermatitis
Our study is the first to compare fungal microbiome changes in patients with atopic dermatitis (AD) before and after treatment with upadacitinib and dupilumab. We found that upadacitinib more effectively restores the fungal microbiome to levels observed in healthy individuals, which may contribute to its superior efficacy in head-and-neck dermatitis (a subtype of AD). The results enhance our understanding of how JAK inhibitors influence the skin microbiome in AD.
Authors
- Ruojun Wang (ORCID: https://orcid.org/0000-0003-1505-6528)
- Yang Li (ORCID: https://orcid.org/0000-0003-0735-8446)
- Zhe Wan (ORCID: https://orcid.org/0000-0001-8088-1677)
- Tingting Li (ORCID: https://orcid.org/0000-0003-2754-9784)
- Ruoyu Li (ORCID: https://orcid.org/0000-0002-2302-3577)
- Tao Rong
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Peking University (CN)
- National Clinical Research (US)
- Peking University First Hospital (CN)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1093/bjd/ljaf095
- Citations
- 1
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.00